Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.
- FROM REGULATOR TO ROADBLOCK: HOW FDA BUREAUCRACY STIFLES INNOVATION [Senate Hearing 119-415] [From the U.S. Government Publishing Office] S. Hrg. 119-415 FROM REGULATOR TO ROADBLOCK: HOW FDA BUREAUCRACY STIFLES INNOVATION ======================================================================= HEARING BEFORE THE SPECIAL COMMITTEE ON AGING UNITED STATES SENATE ONE HUNDRED NINETEENTH CONGRESS SECOND SESSION __________ WASHINGTON, DC __________ FEBRUARY 26, 2026 __________ Serial No. 119-25 Printed for the use of the Special Committee on Aging [GRAPHIC NOT AVAILABLE IN TIFF FORMAT] Available via the World Wide Web: http://www.govinfo.gov __________ U.S. GOVERNMENT PUBLISHING OFFICE 63-835 PDF WASHINGTON : 2026 ======================================================================= SPECIAL COMMITTEE ON AGING RICK SCOTT, Florida, Chairman DAVE McCORMICK, Pennsylvania KIRSTEN E. GILLIBRAND, New York JIM JUSTICE, West Virginia ELIZABETH WARREN, Massachusetts TOMMY TUBERVILLE, Alabama MARK KELLY, Arizona RON JOHNSON, Wisconsin RAPHAEL WARNOCK, Georgia ASHLEY MOODY, Florida ANDY KIM, New Jersey JON HUSTED, Ohio ANGELA ALSOBROOKS, Maryland ---------- McKinley Lewis, Majority Staff Director Claire Descamps, Minority Staff Director C O N T E N T S ---------- Page Opening Statement of Senator Rick Scott, Chairman................ 1 Opening Statement of Senator Kirsten E. Gillibrand, Ranking Member......................................................... 2 PANEL OF WITNESSES Annie Kennedy, Chief Mission Officer, Everylife Foundation for Rare Diseases, Washington, D.C................................. 4 Jeremy Schmahmann, MD, Director, Massachusetts General Hospital Ataxia Center, Boston, Massachusetts........................... 6 Bradley Campbell, President and CEO, Amicus Therapeutics, Princeton, New Jersey.......................................... 8 Cara O'Neill, MD, FAAP, Chief Science Officer, Co-Founder, Cure Sanfilippo Foundation, Columbia, South Carolina................ 10 APPENDIX Prepared Witness Statements Annie Kennedy, Chief Mission Officer, Everylife Foundation for Rare Diseases, Washington, D.C................................. 34 Jeremy Schmahmann, MD, Director, Massachusetts General Hospital Ataxia Center, Boston, Massachusetts........................... 41 Bradley Campbell, President and CEO, Amicus Therapeutics, Princeton, New Jersey.......................................... 45 Cara O'Neill, MD, FAAP, Chief Science Officer, Co-Founder, Cure Sanfilippo Foundation, Columbia, South Carolina................ 51 Questions for the Record Annie Kennedy, Chief Mission Officer, Everylife Foundation for Rare Diseases, Washington, D.C................................. 93 Bradley Campbell, President and CEO, Amicus Therapeutics, Princeton, New Jersey.......................................... 96 Statements for the Record ALS Association Statement........................................ 101 Huntington's Disease Society of America Statement................ 103 Jeremy D. Schmahmann, M.D., Statement............................ 115 Little Hercules Foundation Statement............................. 165 Individuals with Rare Diseases' Statements for the Record........ 169 Taxpayer Protection Alliance Statement........................... 452 FROM REGULATOR TO ROADBLOCK: HOW FDA BUREAUCRACY STIFLES INNOVATION ---------- Thursday, February 26, 2026 U.S. Senate Special Committee on Aging Washington, DC. The Committee met, pursuant to notice, at 9:35 a.m., Room 216, Hart Senate Office Building, Hon. Rick Scott, Chairman of the Committee, presiding. Present: Senator Scott, McCormick, Johnson, Moody, Gillibrand, Kim, and Alsobrooks. OPENING STATEMENT OF SENATOR RICK SCOTT, CHAIRMAN The Chairman. Good morning. The U.S. Special Committee on Aging will now come to order. Today we are here to ask a simple but important question, is the FDA doing everything Congress intended it to do to quickly get safe, effective treatments to patients with rare diseases who cannot afford to wait? For more than 30 million Americans living with a rare disease, making sacrifices every day is just a part of life, but something they cannot afford to give up is time. Time means the ability to walk. Time means independence. Time means being able to speak, eat, or even recognize a loved one, and too often, time is exactly what patients lose while therapy sit in regulatory limbo. Growing up, I saw firsthand how a rare disease can affect a family. My family didn't have health insurance, and my brother had a rare hip disease. My mom had to drive 200 miles round trip just so he could get the care he needed. She made that sacrifice because care couldn't wait. My brother couldn't afford to sacrifice time. Congress has been clear. On an overwhelmingly bipartisan basis we have given the FDA flexibility to move faster for patients with serious and life-threatening conditions. In 2016, Congress passed the 21st Century Cures Act. In that bill and other bills that followed, Congress gave direction to the FDA, encouraged the use of real-world evidence, highlighting that rare disease drug development requires adaptability and urgency. These laws are meant to help cut through bureaucratic delays and give patients access to the care and cures they so desperately need. Yet here we are, 10 years later, hearing from patients, physicians, and drug developers that the system is not working as Congress intended. I have heard from Commissioner Makary that he is working hard to fix longstanding problems at the FDA and I want to thank him for the work he is doing to try and make a strained system work better for patients. However, advocates here today will describe inconsistent review practices, shifting standards, and redundant, often late appearing data requests that in many cases may not be driven by safety concerns but by an overly cautious and rigid approach that puts bureaucratic processes ahead of patients. As we will hear, the human cost of this regulatory slow walking is real. Many of the patients affected by these delays have no other treatment options. Patients from every State come and talk to our offices, and I am sure the same thing with the Ranking Member, sharing their irreversible declines in health that happen while they or someone they care about waits for a treatment that might never come. It is heartbreaking to hear from families who are left watching their loved ones deteriorate, while promising therapies remain stuck in review. Meanwhile, small biotech companies struggle to survive years of uncertainty, even when their science is sound. Beyond individual patients, there are serious national security consequences that come with the FDA's inaction and delays. Our adversaries have been accelerating their drug development and approval, attracting investment, talent, and clinical trials. FDA inaction here at home creates an economic and national competitive issue. Let me be clear, this hearing is not about weakening safety standards. Safety must always come first, but safety and speed are not mutually exclusive. A system can protect patients while still acting with urgency, transparency, and common sense. Some of you may be asking why the Senate Aging Committee is tackling this issue when so many of those impacted by issues with rare disease treatments are young. Here is why. Part of caring for America's aging population is making sure that more Americans are given the opportunity to grow old. It may sound cliche, but we are all aging. If something is standing in the way of a younger American making it to their senior years, it is absolutely the business of this Committee and something we need to try and fix. It is my hope that today's hearing will serve as a useful tool to help us understand what we can do to bring accountability, transparency, and efficiency to the process. We are joined by an incredible panel of witnesses here today representing a wide range of perspectives, but all working toward a better future for people living with rare diseases. Now, we have a lot of members in the crowd that are here because rare disease drugs are very important to them, and I want to thank everybody for being here. Now, I would like to recognize Ranking Member Gillibrand for her opening statement. OPENING STATEMENT OF SENATOR KIRSTEN E. GILLIBRAND, RANKING MEMBER Senator Gillibrand. Thank you, Chairman Scott. I really appreciate you calling today's hearing. Thank you to our witnesses and the advocates who are here for Rare Disease Day on the Hill. It makes a big difference that you come together to make sure your loved ones are being heard and that the challenges and struggles that you go through as families and supporters are being understood by lawmakers. Every one of us in this room today knows that when we have a friend, or a loved one, or a family member who has a rare disease, that the most important thing is finding a cure, getting the treatment, and making sure they survive. A disease is considered rare if it affects fewer than 200,000 people, but rare diseases actually aren't that rare. One in ten Americans is living with a rare disease. As you know, many of these patients face substantial unmet medical needs. Because it can be really difficult and expensive for companies to develop these treatments and the FDA to evaluate them, Congress has provided the agency with significant regulatory flexibility to encourage both biotech innovation and rare disease therapies. These include authorizing the accelerated approval pathway to speed up the drug review, establishing programs like the Rare Disease Endpoint Advancement Pilot to bolster novel endpoint development, and strengthening and expanding the use of patient experience data and real-world evidence in drug reviews. These mechanisms are designed to help improve access to novel treatments for our patients, and they are supposed to provide drug sponsors with a predictable and consistent approach to addressing regulatory science challenges that are unique in rare disease therapy development and review, like designing complex clinical trials, developing appropriate endpoints, and using real world evidence, but it is not working how it should be. FDA's approach, transparency, and flexibility varies widely between its offices, divisions, and centers. I have seen a pattern of hesitation to use authorized flexibilities, limited communication with drug sponsors, failure to incorporate patient experience in real world evidence reviews, and FDA shifting its regulatory position on trial design at the last minute, rejecting drug applications, and requiring new clinical trials the sponsor may be unable to perform. This is heartbreaking for patients, and it is why we can't afford delays and disruptions in treatment. Rare diseases can progress rapidly, cause irreversible harm, and in some cases premature death. This is also frustrating for drug sponsors who face increased costs and delayed timelines that impact the viability of their clinical trials, particularly in the United States. Uncertainty shapes behavior across the biotech ecosystem. Without consistency and predictability, drug sponsors will continue to struggle with seeking FDA approval and will take their clinical trials elsewhere, like to China. This is bad for business, and it is bad for patients. If we want the U.S. to remain the global leader in biotech and we want American patients to have access to these novel treatments, things need to change. Congress must hold the FDA accountable. We must make sure FDA fixes its inconsistent and unpredictable application of regulatory flexibility. It is essential for supporting innovation, while upholding the highest standard for safety and efficacy, in the approval of these rare disease drugs. FDA appears to be moving in the right direction. With the rare disease evidence principles, the rare disease innovation hub, proposing new pathways for approval and trying to hire more reviewers, but it doesn't matter what agency leadership puts in a press release. It is about execution and implementation across all levels of that agency. Consistency from top to bottom. Congress will ensure that happens by conducting oversight, encouraging application of authorized flexibilities, and providing adequate resources to restore agency capacity. I look forward to hearing from our witnesses and working with this committee to hold the FDA accountable because rare disease patients cannot wait. The Chairman. Thank you, Ranking Member. I would like to welcome our witnesses, experts who are here to talk about how serious this issue is and the steps we can take to ensure patients with rare diseases are not left behind by regulatory delay. First, I want to recognize Annie Kennedy, Chief Mission Officer at the EveryLife Foundation for Rare Diseases. Ms. Kennedy is a nationally recognized leader in rare disease policy and patient advocacy and works directly with patients, caregivers, and families navigating the drug development and approval process. EveryLife represents the voices of rare disease communities across the country, and has long advocated for patients centered policies, regulatory flexibility, and timely access to life-saving therapies. Thank you for being here, and please begin your testimony. STATEMENT OF ANNIE KENNEDY, CHIEF MISSION OFFICER, EVERYLIFE FOUNDATION FOR RARE DISEASES, WASHINGTON, D.C. Ms. Kennedy. Thank you, Chairman Scott, Ranking Member Gillibrand, and distinguished members of the Committee for convening this critical hearing. I am Annie Kennedy, Chief Mission Officer for the EveryLife Foundation for Rare Diseases. I am honored to be here alongside the hundreds of advocates who have joined us for Rare Disease Week on Capitol Hill. Collectively, we are representing the more than 30 million Americans living with rare diseases. Today, there are more than 10,000 known rare diseases, about 70 percent of which start in childhood. For small patient communities facing progressive diseases, time is a commodity. Traditional large placebo-controlled trials are often neither feasible nor ethical when considering the challenges and urgency of rare diseases. Beginning with the passage of the Orphan Drug Act in 1983, your leadership has provided tools that have rocketed the U.S. into the most competitive developer of rare disease products. Each landmark law since has reshaped our landscape. In fact, tomorrow marks an anniversary of another watershed moment for our community here on Capitol Hill. The MD Care Act hearing convened in this exact same hearing room, presided over by Senator Arlen Specter, included a 13-year-old named Benjamin Cumbo. Twenty-five years ago, I watched with great pride as Ben asked Congress for actions that could help cure him and his friends so that he could achieve his dreams of growing up, having a girlfriend, and serving his country. Congress did respond. In that time, Congress has built a framework that incentivizes rare product development, authorizes regulatory flexibility, creates new pathways to approval, and embeds patient experience into review. While fewer than five percent of rare diseases currently have an FDA approved treatment, nearly 1,400 orphan-designated therapies are now changing the lives of patients and families. Recently, this momentum has shifted. We are here today because our community has experienced worrisome trends with devastating consequences. While we are heartened by recent announcements of therapy development initiatives, such as the Rare Disease Evidence Principles Framework and the Plausible Mechanism Pathway and are eager to work with the agency on their implementation, our rare disease community has experienced a series of product application actions that seem misaligned with these recent public pledges to expand the use of regulatory flexibility. Since the start of 2025, we have seen at least 23 complete response letters declining to approve rare disease therapies, many under accelerated approval, that suggest a hesitation to apply regulatory flexibility through surrogate endpoints, natural history studies, and external controls. At that same time, advisory committee meetings for drugs and biologics declined by 65 percent compared to 2024, reducing opportunities for external expertise and patient insights to inform complex rare disease product decisions. We asked families who would been personally affected by recent regulatory decisions to reflect on their impact. These stories will be shared for the record. Story after story spoke to chilling consequences of recent regulatory delays and clinical trial hurdles. As one mom shared about her son, Stone. My son is now receiving this experimental treatment, and he is thriving. For the first time since his diagnosis, his doctors have told us, with this treatment, a near normal lifespan is within reach for a disease that once came with a teenage expiration date that is nothing short of extraordinary. We are now living in fear, not because science failed, not because companies stopped fighting rare diseases, but because of regulatory inconsistency. We are here today because congressional action is needed to ensure that this generation of patients will benefit from our existing rare disease treatment pipelines. We ask that Congress engage FDA to clarify its approach to accelerated approval for rare diseases, its consistent application of regulatory flexibility, and to urge the resumption of advisory committee meetings so that external expertise informs complex reviews. We also urge Congress to resource the Rare Disease Innovation Hub to strengthen cross center coordination and to establish the Rare Disease and Condition Advisory Committee and a science focused drug development initiative. In closing, 25 years ago, I stood in this room filled with rare families. Today, advances in science have put life-altering treatments within reach for many, but those advances were not in time for those who were in this with me 25 years ago. While Ben achieved many of his dreams, he died two days before receiving his master's degree. We now have the opportunity to ensure that this generation of rare disease patients will benefit from today's therapy development pipelines. Each time a promising therapy faces delays or demise, investment wanes, future scientific promise is unfulfilled, and lives are lost. Time is the most precious commodity for our rare disease community. As Stone's mom implored while writing from his hospital bedside, we are closer than ever to rewriting the future of these diseases. Please don't let my generation become the next group of mothers who stand at gravesides instead of graduations. Thank you. The Chairman. Thank you. Thank you, Ms. Kennedy. Now, I would like to introduce Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical School, Founding Director of the Ataxia Center at Massachusetts General Hospital, and Principal Investigator for the Laboratory for Neuroanatomy. I said that correct, right? He is a leading neurologist who treats patients with progressive and neurodegenerative diseases where time and access to treatment are critical. He has seen firsthand the consequences of delayed access to care and the irreversible loss patients can experience while waiting for regulatory decisions. His testimony will round today's discussion and the real- world clinical impact these regulatory delays have on patients and families. Thank you for being here. Please begin your testimony. STATEMENT OF JEREMY SCHMAHMANN, MD, DIRECTOR, MASSACHUSETTS GENERAL HOSPITAL ATAXIA CENTER, BOSTON, MASSACHUSETTS Dr. Schmahmann. Chairman Scott, Ranking Member Gillibrand, members of the Committee, thank you for convening this hearing, and for the opportunity to testify, and for your remarkable opening statements. My name is Jeremy Schmahmann. I am the Martha and Robert Fogelman Chair in Ataxia, and Cerebellar Neurology at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School. I started the first Ataxia Center in the country, and I have cared for patients with spinocerebellar ataxias for 45 years. I am the site principal investigator for Biohaven's study of troriluzole in ataxia and my comments today reflect my personal and professional opinion, not necessarily that of my employer. Senators, please help us fix the FDA. It has rejected troriluzole, a drug that is safe--the first treatment to improve quality of life and slow progression in spinocerebellar ataxia. My patient Steve, for example, developed spinocerebellar ataxia type 3, also known as Machado-Joseph disease, in his late 30's. Like his mother before him, he will become increasingly disabled, will need to use a wheelchair, become bedridden, and die young, but since starting troriluzole a year ago, he has not changed. Mary, in her late 40's, has type two. After six and a half years on troriluzole, she has not change. These inherited neurodegenerative diseases worsen inexorably and in this business, staying the same is success. Like other rare diseases, ataxia is difficult to study, deteriorates slowly, and manifests differently even within families. There are 15,000 ataxic patients in America. Some affect hundreds of people, some just a few. Now, Congress, as you have told us, recognized these challenges and passed legislation mandating that FDA use regulatory flexibility and real-world evidence in rare diseases like ataxia. The drug riluzole, used to treat ALS for 50 years, was reported to improve ataxia. Based on this, and the plausible mechanism of action in spinocerebellar ataxia, Biohaven developed troriluzole, which metabolizes into riluzole, but is taken once a day with better brain penetration and fewer side effects. Early in the drug's development, an ataxic patient who stopped treatment after a year of open label therapy insisted they go back on troriluzole because they told us their condition worsened after stopping the drug. Biohaven, to their credit, provided troriluzole to these patients and ran a one-year, double-blind placebo-controlled study. Patients with spinocerebellar ataxia type three improved compared to placebo. They were falling less, and they had fewer injuries. Biohaven requested approval of troriluzole for spinocerebellar ataxia type three based on these results. The FDA refused to review the new drug application. Biohaven obtained FDA feedback and used a revised protocol to follow patients on drug for another three years, comparing them with patients in two natural history studies. In this real- world evidence study, troriluzole showed significant improvement across nine pre-specified FDA endpoints, slowing disease by 50 to 70 percent. This is a dramatic result that was supported by patient and physician feedback. We were all shocked when FDA denied approval of this safe drug that makes people better. I wrote six letters to FDA leadership between 2023 and 2025, co-signed by 17 ataxia colleagues, asking FDA to review the application again and work with Biohaven to make the drug available, if necessary performing post-marketing studies. I never heard back. Now, 300 patients, stable on troriluzole, will have to come off drug, and they are distraught. I met three times with FDA's Center for Drug Evaluation and Research. On each occasion, they did not heed the patients or the experts or considered the science. One panel member said to me, why should I listen to you? The FDA's proposed path forward is another placebo- controlled trial that will take five to eight years, or a randomized withdrawal of the drug from patients benefiting from it. If this happens, patients on placebo will die. I believe this to be unethical, lacking charity, mercy, or kindness. Senators, please, save our patients' lives. Use your authority to require that FDA consider real-world evidence and applies the regulatory flexibility you have legislated, and in so doing restore transparency, integrity, and competence to the agency. Thank you. The Chairman. Now, I would like to recognize Ranking Member Gillibrand to introduce our next witnesses. Senator Gillibrand. Thank you, Mr. Chairman. I want to introduce our next witness, Bradley Campbell. Mr. Campbell is the President and CEO of Amicus Therapeutics, a biotechnology company focused on discovering and developing new medicines for people living with rare diseases. During his tenure at Amicus, he led the global commercialization of Galafold, a medication used to treat Fabry disease in adults, which was approved by the U.S. Food and Drug Administration on an accelerated basis. Mr. Campbell brings over 20 years of experience in the rare and orphan disease fields. You may begin your testimony. STATEMENT OF BRADLEY CAMPBELL, PRESIDENT AND CEO, AMICUS THERAPEUTICS, PRINCETON, NEW JERSEY Mr. Campbell. Thank you very much, Chairman Scott, Ranking Member Gillibrand, the rest of the Senators on the Committee. It is my privilege to be here today to speak to you about our experience in developing drugs for people living with rare diseases. I am also honored to be alongside my fellow panelists. I feel far less qualified than they to speak today, but I hope I can share some perspectives on the challenges and opportunities we have to help fix the system. I have had the privilege to work at Amicus for the last 20 years and have dedicated most of my professional career to developing new treatments for people living with rare diseases. I thought I could begin with a patient story that I think captures the spirit of the testimony here today and the conversation we are having. At a recent patient meeting, we were discussing patient experience data and how we might make endpoints for clinical trials more meaningful for patients. During a break, a young woman with Pompe disease took me aside and said, what would be most meaningful for her is if she could breathe on her own for just one minute. That would make the difference between her life and her death. This is not an approvable endpoint in Pompe disease, of course, but she depends upon a mechanical ventilator to breathe. If that ventilator fails, if the battery dies, if an aid fails to clear a mucus plug, just that 60 seconds of her own breath could make the different between her life and death. I think that comment is a very powerful reminder of why patients and caregivers must help us design better clinical studies with real endpoints that make a difference for them. We can't ask patients to wait for years before approved treatments come when the difference between life and death can be that single breath. I think the rare disease innovation ecosystem in the United States has made enormous progress over the last 20 years, but it must now again adapt in speed, agility, and flexibility to keep the pace of innovation. One of our own development experiences at Amicus I think sheds light on how regulatory flexibility and working together with sponsors and regulators can make a real difference in drug development. When we were developing our medicine Galafold for Fabry disease, we learned in early studies that in some patients the drug worked and some patients it didn't. Through careful data analysis and close collaboration with the FDA and regulators around the world, we developed an assay that could identify which of the thousands of genetic variants that cause Fabry disease might best respond to the therapy, and just as importantly, which ones may not. The FDA ultimately incorporated that assay into our label and approved the first ever oral precision medicine for people living with Fabry disease. What does that mean? That means when sponsors and regulators work together, the result was an oral treatment option that has saved thousands of patients' years of biweekly infusions. We know rare diseases are biologically complex. We know they are difficult to study. As we sit here today, 95 percent of the more than 10,000 known rare diseases lack an FDA- approved treatment. I think that is statistic many of us are familiar with, but if you fast forward that pace of development, it will take us 150 years to only treat half of the remaining rare diseases. Small and mid-sized biotechnology companies like Amicus, Biohaven, and others are the engine of rare disease innovation, but they can only succeed if the regulatory system adapts along with unmet medical need. I think there are three practical areas that we can work together to improve that very system. First, we must start clinical trials faster. We know in other countries, those trials start in weeks, not months. We can reduce administrative requirements, leverage single IRBs, use AI and other digital tools to get into the clinic faster. We also must find better ways to measure efficacy. We can use biomarkers, innovative endpoints, accelerated approvals. These are things the FDA has at its disposal right now, but we must use them more and we can make manufacturing inspections and rules work better. The single biggest delay oftentimes is inspections for getting patients access to medicines. The FDA has tools like remote interactive inspections and relying on global regulators to reduce that inefficiency and let me close with just one final story. At a patient meeting last year, a man with Fabry disease told us when he was diagnosed in his 30's, he stopped saving for retirement because he thought there was no reason to think he could live that long. Fast forward 15 years, Fabry disease is now a treatable disease. Advancement in treatments have changed that trajectory and for the first time he is thinking about a future he thought he would never have. I look forward to working together with the members of this Committee, and indeed with the regulators, the broad community here focused on rare diseases to find ways to ensure that we have a flexible, adaptable, agile regulatory system that can keep pace with modern innovation. Thanks so much for the opportunity to testify and I look forward to taking your questions. Senator Gillibrand. Thank you, Mr. Campbell. I want to move to introduce our next witness, Dr. Cara O'Neill. Dr. O'Neill is the Co-Founder and Chief Science Officer at the Cure Sanfilippo--the Cure Sanfilippo Foundation, dedicated to accelerating scientific development on disease and empowering families with the resources they need to navigate their journey. Dr. O'Neill founded the foundation after receiving her daughter, Eliza, Sanfilippo's diagnosis in 2013. At the foundation, Dr. O'Neill leads patient focused research efforts and awareness, working to bridge the gap between scientists, clinicians, industry, and family. She was awarded the International 2020 Patient Advocacy Leader Award by World Symposium for exceptional contributions. You may begin your testimony. STATEMENT OF CARA O'NEILL, MD, FAAP, CHIEF SCIENCE OFFICER, CO-FOUNDER, CURE SANFILIPPO FOUNDATION, COLUMBIA, SOUTH CAROLINA Dr. O'Neill. Thank you, Chairman Scott, Ranking Member Gillibrand, and members of the Committee. On behalf of 15 million children with rare diseases in this country, I thank you truly for your concern. I am Cara O'Neill, Chief Science Officer at Cure Sanfilippo Foundation, a Pediatrician, and mom to Eliza who has an ultra- rare genetic disease called Sanfilippo Syndrome, or MPS3, one of many forms of childhood dementia leading to progressive, irreversible brain damage. I would like to first acknowledge the critical public service of FDA and its staff who shoulder complex and heavy workloads every day. We know the pressures are significant because we feel it too. Of late, we have seen many press releases highlighting new FDA policies and programs, which encourage us to look out into the future with hope, but today, the Committee has called us here with the recognition that current regulatory barriers are significantly impacting patients right now, and never more starkly than for degenerative conditions where time is the most crucial factor and where every regulatory flexibility must be leveraged to meet this uniquely urgent need. We can see this illustrated in a story of three girls with the same deadly disease, but very different lives. Isabelle, or Izzy, was the first child with Sanfilippo that my husband and I met after our own daughter Eliza's diagnosis. Izzy was just 11, and the disease had already taken a tremendous toll. She could no longer walk independently, taking only a few steps if her mom held most of her weight. Izzy had lost the ability to speak years before and could no longer eat or drink without choking, so relied on a feeding tube. She had seizures and increasingly severe abnormal movements that twisted her arms and legs into painful positions. During one visit, Izzy's mom shared that she had come to accept this disease would take her daughter's life, but what she said next has always stuck with me. She said, in truth, I fear her suffering more than I fear death. At that time, my Eliza was close to four and in an extremely hyperactive stage of the disease, but she sang and talked with us. She played dress up and clapped around the house in my high heels. She rode her tricycle everywhere. She looked so healthy, but what was going on inside her body and brain was a much different picture. Meeting Izzy put us face to face with Eliza's future, the concrete and cruel reality of what this disease would do. A medicine didn't come in time for Izzy. She suffered greatly and passed away just a few weeks before her 15th birthday. For decades, we have known the cause of this disease. We can precisely measure the levels of toxic biomarker to determine whether a treatment is working and now we have the science to treat it. Thanks to NIH funding and support from nonprofit foundations, including our own, a promising gene therapy was developed and propelled toward clinical trial at nationwide Children's Hospital in Ohio. While we anxiously were awaiting news the trial will begin, back at home we watched Eliza's sentences becoming shorter, her words less frequent. She became agitated and hardly slept. The disease was taking hold. Two years later, in May 2016, the clinical trial finally began and Eliza, then six and a half, was so very lucky to be the first child to receive that gene therapy. It was her chance at a life different from Izzy's--a chance to grow up. Now at 16, it is clear that therapy changed her life. She surpassed average life expectancy, runs on the beach, plays in the water, uses picture cards to tell us how she is feeling and what show she wants to watch on TV. She can feed herself and goes to school every day. These are simple but incredibly meaningful abilities that have a huge impact on her daily life, and children treated with higher doses earlier in life have even more remarkable outcomes. Like Caroline, who is now 10. She can read, play on a softball team, and learn to ski on her recent family vacation. Despite these breakthroughs and nearly 10 years after the trial began, families outside the trial are still waiting for access. Why? Because last summer the drug was denied approval, not because of safety or how the children were benefiting, but for questions about manufacturing. While this is an important issue, FDA could have used its flexibility to continue reviewing the application while addressing questions in parallel. You see, early on, trial data confirmed the drug's mechanism was more than just plausible, it was biologically effective, showing significant reduction of toxic biomarker within just six months after treatment in all the children. Granting accelerated approval based on this biomarker would have brought treatment access to children years earlier, preventing further brain damage and changing the lives of so many children, like Sadie, who is here today--who is still waiting. This same drug application was recently resubmitted, but FDA issued another denial asking for yet more paperwork before agreeing to review it again. Congress has given FDA the tools of flexibility it needs to accelerate approvals for these devastating diseases, but sadly flexibility and speed are not actually what most rare disease patients are witnessing. Transformative therapies are at FDA's doorstep and so, with great respect, families are pleading for FDA to unlock the door and move with urgency so that our children can have a chance at the life they deserve. Thank you. The Chairman. Thank you for your testimony. Thank you, Mr. Campbell, for your testimony. Now we will go to questions. Senator Johnson. Senator Johnson. Thank you, Mr. Chairman. Again, I have to commend you for another excellent hearing here. At the start of the hearing, I received a text from Laura McLinn, who reminds me that 10 years to this day, as Chairman of Homeland Security I held a hearing titled, Connecting Patients to New and Potential Life Saving Treatments. Her son, Jordan, who suffered from Duchenne Muscular Dystrophy testified at hearing--was certainly present there. Two years later, that resulted in Right to Try, which was not easy to pass. I had to hold up the FDA user fee bill, had to water down Right to Try quite a bit to make sure that Big Pharma wouldn't sabotage it. They did sabotage it over in the House, but because of President Trump's leadership, he forced the House to pass the Senate version. Its main benefit is its name. It is very limited in its application, unfortunately. People have the right to try. Laura has also begged me, begged me in a text to mention Ataluren and Deramiocel, two investigatory drugs that are also being held up by the FDA for Duchenne Muscular Dystrophy. I think we probably are going to need another piece of legislation, probably Right to Try 2.0-- something that is going to be far more effective than the current Right to Try, but I will tell you, reading this testimony this morning, you can maybe tell just by my passion, it enraged me. It enraged me that these families, these patients are being denied effective treatments because of the regulatory roadblocks. Quick story and again, I want to ask questions, but a quick story. After I met the Duchenne Muscular Dystrophy community, they went up before a panel of FDA--this was probably in 2016, 1917, or 1918--begging. There are about 60 Duchenne Muscular patients' families begging the FDA, please approve this investigatory drug for our children. Again, time is muscle, time is brain and that panel, I don't know who sat on it, listened to those 60 families begging them and said no, just like they said no--and I can't even pronounce these diseases and drugs. They say no time and time and time again. That has to change. Congress is directing the FDA, be more flexible--say yes. You know, these patients understand the risks. They ought to have the right to try. Dr. Schmahmann--am I pronouncing that right? Dr. Schmahmann. Yes, sir. Senator Johnson. I don't want you throwing anybody under the bus because I don't want this to impact future approvals but describe your meetings with CDER. To me, it is shocking to have one of those members of that panel say, why should we listen to you? Well, because you are a doctor at Harvard. You are treating patients. You are having success. You are giving them a new lease on life, and you have got bureaucrats inside these agencies saying, why the hell should we listen to you? I want you going into greater detail--describe what those meetings are like. Dr. Schmahmann. Thank you, Senator. We have heard a few words a few times. Heartbreaking as the experience of patients and families going through this and the compassion that is required. I saw none of that in the three meetings with the FDA. The members of the panel were like talking to a brick wall. There was no engagement, no dialog. In fact, they said as much, this is not a dialog, this is not a collaboration. They do not seem to see the suffering of the patients, and they didn't hear the science. They were rigid and inflexible and unyielding. The FDA worked with the company initially, but then they changed their mind later, and so, as the studies unfolded, everything came to a grinding halt. This drug in particular is safe. It metabolizes into a drug that has been there for 30 years in the market and is safe. Patients say it works. The doctors say it works. The study shows it works. The double-blind first study showed it worked. The real- world evidence shows it works. Patients behind me, every one of them, talking to them yesterday, say it works. This drug works. To paraphrase the Senator, what is their problem? My experience of the people on that panel, three times, as a private citizen coming for the first time to the FDA, was deeply distressing. Senator Johnson. I have already texted Dr. Tracy Beth Hoeg and told her I have read your testimony. I will be sending her your testimony. I hope she listens to this. If I could just take a couple more minutes, Dr. O'Neill, you are obviously personally impacted by this. Can you describe any meetings you have had similar to what we just heard? Again, the American people need to understand what these regulators are doing and not doing. Dr. O'Neill. Dr. O'Neill. Thank you. You know, I will say that my interactions with regulators have been kind, so maybe a bit of a different perspective is they have listened. They have been interested to hear what we had to say. To hear the patient perspective. I think where we are challenged is that we don't see that translated into regulatory action. Some of the decisions that are coming out are not benefiting patients right now. Listening is great, but two-way conversation and collaboration is actually what is needed, and greater transparency in how patient experience data and patient input is actually being integrated into these decisions. Senator Johnson. My guess is that panel for Duchenne Muscular Dystrophy back in 2017 or whatever probably listened very nicely to the families, but they still said no. That is an unacceptable answer. Again, you have my commitment. I am going to delve into this. We are going to right these wrongs. Thank you. Mr. Chairman, this is again an excellent hearing. We have got to followup on this. This is just completely unacceptable. Thank you The Chairman. Thank you, Senator Johnson. Senator Alsobrooks. Senator Alsobrooks. Thank you so much, Chair Scott. Also Ranking Member Gillibrand. I am so grateful to be here today joined by so many patient advocates, caregivers, family members. I have heard from many Marylanders living with rare diseases and from their families, including dozens who have visited my office this week to share their priorities and their concerns. As I underscored with the NIH Director a few weeks ago, patients suffering from devastating diseases do not have time to wait for needless delays to critical cures. For Marylanders with rare diseases, delayed access is not just an inconvenience, it is a matter of life or death. For many with rare conditions, clinical trials are their last and best hope. These patients also depend on a regulatory process that is science driven and capable of turning research into real treatment. Instead of strengthening those foundations, this Administration is constantly disrupting clinical trials, slowing innovation, and undermining the pipeline to cures. Scientific integrity should always guide decision-making, and we must protect the firewall between the Food and Drug Administration and political influence. President Trump and Secretary Kennedy continue to decimate critical parts of that system. The instability they have caused ripples across families, physicians, researchers, and innovators, and patients pay the price. Ms. Kennedy, I would like to ask, over the past two weeks, we saw a striking example of political interference at the FDA involving a seasonal mRNA flu vaccine from Moderna. The agency first declined even to review the application, then reversed course just one week later after revised regulatory approach. The abrupt change raised serious concerns about transparency, predictability, and political influence in what should be a scientific process. An episode many have described as regulatory whiplash. What does that kind of volatility signal about how the FDA is functioning right now, and why does that matter for rare disease reviews that depend on regulatory consistency? Ms. Kennedy. First of all, thank you so much, Senator, for being here and for all of you being here today, and for this important issue. I think first it is important to say that I am not an expert in vaccines, and I am here really to focus on rare disease, but I appreciate the question really asking about the trends that we are seeing and us being here really trying to follow the trends and understand what that means for rare disease. I also agree with Dr. O'Neill that we have seen real intention from career staff and staff scientists at FDA around their engagement, but what we are concerned about is, to your question, what seems to be reversals in decisions, where there had been previous agreement, previous work with sponsors that was directing sponsors to move in one direction, and then regulatory decisions seemed to be yielding different decisions at this point. As I stated in my testimony, we have seen recently 23 complete response letters issued in rare diseases that are delaying access to the patient community and having devastating consequences to our community. Many of those actually are decisions that are reversals in regulatory agreements that have been made previously. Additionally, we are very concerned that previously, if there were to be a complex decision that needed to be worked through between a sponsor and the agency, an advisory committee would have been convened, and we have seen 65 fewer advisory committees convened in 2025 than 2024. In fact, none since July. We are very concerned that the regulatory tools that are at the disposal of the agency to really work through some of these really complex decisions aren't being utilized. Senator Alsobrooks. Thank you. Just very quickly, if I can also go to Ms. O'Neill. Finding new cures doesn't happen overnight, and it rarely happens in a single year. Breakthrough therapies are built over decades of careful scientific work and discoveries, and NIH funded laboratories form the foundation for treatments that later move into clinical trials through regulatory review and ultimately into patient care. When NIH research capacity is disrupted, as we have seen, and weakened, how does that set back the search for new cures long before therapies ever reach the FDA? Dr. O'Neill. Thank you for your question. The NIH is a critical source of funding for innovation in this country and scientific innovation. It is interesting that when there were disruptions and uncertainty in the funding, we received a flood of requests about funding from our small non-profit foundation. I think non-profit foundations across the country were seeing that and, you know, we are not equipped to take up all of the pre-clinical and transformative science that NIH can do. The role of the NIH in supporting innovation is huge. Senator Alsobrooks. Thank you. The Chairman. Thank you, Senator. Senator McCormick. Senator McCormick. Thank you, Mr. Chairman and thanks to you and the Ranking Member for convening this and thank you all so much for being here today to help bring some of these critical issues to Americans and Pennsylvanians to light. Ms. Kennedy, more than 30 million Americans live with rare diseases, yet fewer than five percent have an approved treatment. As you mentioned, since early 2025, the FDA has issued at least 23 complete response letters for rare disease therapies, while advisory committees use has declined dramatically. When late-stage rare disease applications raise concerns, what alternatives to issuing a complete response letter should the FDA use, including advisory committees or structured post- approval commitments, to resolve issues without restarting the entire process? Ms. Kennedy. Thank you. We appreciate that question. FDA has at its disposal, thanks to Congress, many types of engagements between sponsors and the agency. Many of those have been made possible thanks to the user fees. We are concerned that many of those meetings and meeting types aren't occurring, and that the CRLs are being utilized as a way to perhaps maybe even clear the docket or create delays. There could be a lot of reasons why that might be happening, but there are meeting types that have been implemented that could enable engagement to answer questions that sponsors, and the agency might have. We saw actually the agency deploy this during the pandemic, the COVID pandemic, where we saw real rapid, real time resolution to a crisis in our country and the agency was able to interact with sponsors. Get questions answered in real time and then we saw that CBER tried to operationalize that in other places and spaces. We would really, as a rare disease community, like to see that operationalized within rare disease because we believe that our rare disease community has the urgency and unmet need that matches that of a pandemic, of a crisis. We have individuals in this room who have very limited life expectancies. If we don't address what is happening in rare diseases with that same sense of urgency, they would not be here with us if we were to convene this hearing another year from now. Senator McCormick. Thank you. Thank you for highlighting that urgency, and I think we feel it, and you are helping us to feel it. Thank you for that. Mr. Campbell, just on the issue of accelerating the process. I was taken by the fact in preparing for this that some countries are moving much faster on rare disease therapies. The European Union's FAST-EU program caps multinational clinical trial authorization at 70 days. Australia allows many trials to begin almost immediately after an ethics approval. What is going on here? What will happen if the United States fails to keep pace? What policy changes should we consider in the Congress, given what appears to be a much more streamlined approach in other places? Mr. Campbell. Thank you, Senator. I completely agree. I think, you know, the United States has been the beacon of biotechnology innovation for so many decades, and it is part of why we have more therapies approved today for rare diseases than we did, you now, decades ago. I would acknowledge legislation like the Orphan Drug Act that led to that. As we said in our testimony and many of the panelists here today, we have now stopped keeping pace with innovation and I think one exact point, which I raised in my testimony as well, is speed to clinical trials. For me, on the one hand it is time for patients, and taking weeks, 70 days, would be a remarkable number. I think Congress could work with the FDA to pass legislation to encourage, again, centralized IRBs, leveraging digital technology and artificial intelligence to help us do that. Reducing regulatory requirements. For sure, those things could speed us into the clinic. The other piece, I think, which is sitting behind this is our national competitiveness and in some ways our national security. When we think about Australia, we think of Europe, collaborative nations, etcetera--there are other nations out there that perhaps we see in a different way, and from my perspective, whether you think of that as a security threat or whether you think of that as a threat to getting drugs to patients, in either case, I think Congress can take a leadership role in helping the FDA to speed through that process. Senator McCormick. Thank you all for being here. The Chairman. Thank you, Senator McCormick. Senator Kim. Senator Kim. Thank you, Chairman. Thank you to all of you coming out here. A couple words I just heard that I think really just hit the nail on the head. I would love your reactions to it. When we are talking about all the different problems that we are facing with the FDA, the bureaucracy or the workforce issues, I think the word that really hits it home is urgency. I heard you use that. You know, I heard use that Ms. Kennedy. I feel like that is really what we are talking about here. Is like we need a government that is moving at the speed of urgency that the parents are trying to save their kids, right. Like, that we are struggling to understand what the actual purpose here is and the speed with which we need to move. Look, I got two boys. I got an eight-year-old and a ten- year-old. I would do anything for them, you know. I just like, how do we translate that into the urgency of a government trying to be responsive? I think that is where some of the disconnect hits on so many levels. You know, Mr. Campbell, you talked about it. You used the word national security. I used to work in national security. I was in Afghanistan and Iraq and elsewhere. I saw this government move with urgency when they felt like lives were on the line, but like, why is it that we can't necessarily translate that to another circumstance where there are millions of lives on the lines and people just don't have the time to wait for this? I think that that is really a purpose. How do we talk about this as a national security priority? The same reason we are trying to save lives abroad is the same reasons we are trying to save the lives here at home. Does that make sense to you, Ms. Kennedy? Am I kind of grasping the crux here of what we are trying to push forward? Ms. Kennedy. Yes, Senator, you absolutely are. Congress has recognized this urgency in statute and has enabled the use of regulatory flexibilities, and that is what is reflected in the accelerated approval pathway and the use of surrogate outcome measures and biomarkers in clinical trial design in rare disease. What we are concerned about is that in many of these complete response letters, what we are seeing reflected is FDA, especially in one of the medical product centers, CBER, seems to be the trend that we are detecting backing away from a comfort level or use of the surrogate biomarkers. What we have seen in rare disease is surrogates work. Surrogate biomarkers do save lives. We have more than 250 products that have been approved through the accelerated approval pathway, but fewer than 20 percent of those are for the non-oncologic, non-infectious rare diseases. Which means there is a distinction between what is happening in the rare community that is in this room and the broader rare community. It is really important when we look at those statistics that we sort of look at what the different medical product centers are comfortable with and are doing, and that is why we--we know that the tools are available. We want to ensure that they are being utilized. Senator Kim. Mr. Campbell, I wanted to bring you in on this because, you know, you have talked about this at length. Build off of what we just heard. How would expand use of adaptive trial designs or surrogate endpoints by the FDA lend itself to achieving better outcomes when it comes to rare disease approvals? Mr. Campbell. Yes, I think the first step is just use what we have available to us, right. If you look at oncology, I think in 2024, there were 8,000 different therapeutics in clinical trials that dwarfs the number in rare diseases today. I think a large part of that is the much more welcoming use of accelerated approval and surrogate biomarkers. Our own product, Galafold, was approved on a surrogates biomarker. The competitor product also, Fabrazyme, was approved on a surrogate biomarker and these things work. I get it, you know, rare diseases are biologically complex. It is very difficult to understand how long it is going to take. You can't do randomized control studies in the same way you can with broader disease populations. When it is done right, as in the case of Fabrazyme, 10 years later, after using real-world evidence and a registry, they are able to confirm the original surrogate endpoint, and now it is a fully approved product. For me, the tools are all there. It is really more, as we have discussed, consistency and using the tools that exist. If we were to--oh please, go ahead, Senator. Senator Kim. I just want to jump in here at the end. I mean the urgency on the trials and moving up forward on the approvals, but Mr. Campbell, I also want to raise another issue, which is just how long it often takes to build manufacturing facilities here in the United States. You know, the level of slowness with the inspections themselves. I want that urgency on a manufacturing side as well. You know, what can you be showing us about the decisionmakings that manufacturers are going through especially in terms of being able to build this and manufacture this here in America. Mr. Campbell. Here at home. Thank you so much for the opportunity to address that, so just by background, Amicus, we work with external manufacturers. As a small cap company, we don't have the capital to build our own manufacturing facilities, and we certainly don't have an environment to be able to do that. We work outside the United States. It takes three to five years to just to build a state-of-the-art manufacturing facility for protein therapeutics. It takes another one to two years then to get that facility inspected. You are talking five to seven years from when we want to do this to when it actually has medicine coming off the line for patients. In my mind, it is mutually beneficial to all of us, so create incentives--and they don't have to be financial incentives. Help with permitting. Help with inspections. Give priority to inspections for homegrown manufacturing facilities. Create an environment that is actually supportive of bringing manufacturing at home, versus using, which is what we have seen over the last couple of years, more sticks to try to prevent--probably a more qualified person to speak to this, speaking in background. Let's use incentives instead of sticks to encourage that because I think the United States ecosystem, the patients, all benefit from doing that. Senator Kim. Mr. Chair, you know, we have talked at length here in this Committee about the benefits on so many levels of having that manufacturing here in America, the speed with which we can move, the capabilities. You know, these are some very concrete things that I hope we can followup on and really come up with a game plan here because it is just, honestly, it is just pathetic that we are just not able to do this with a greater level of speed given the skills and the talent and the resources of our country. We can and should be doing better. Thank you for holding this hearing today. The Chairman. Thank you, Senator Kim. Senator Johnson, do you have some more questions? Senator Johnson. Yes. Thank you, Mr. Chairman. I mean, I think the elephant in the room here is, so we have got the laws in place. They maybe could be beefed up, but I think it is a personnel issue, right. I fear that not even necessarily the heads of the agencies, but possibly bureaucrats that have been there for decades, for whatever reason, they don't like a particular drug, and so they are able to sabotage it. My question, how can we overcome the inconsistency from, you know, one bureaucrat to the next bureaucrat, changing administrations, or quite honestly, you know, a particular bureaucrat that has been in there for decades that just keeps blocking things. I mean, how do you get to the personnel issue? I will start with you, Ms. Kennedy. Ms. Kennedy. I think my experience differs from some on this panel in that we have seen great examples of models where we have had public meetings and public workshops where FDA has come together with the patient community, which I think is an incredibly important mechanism, to have meetings where we can have regulatory agreement around the use of certain innovative models in clinical trial design, surrogate endpoints, natural history studies as a control arm that had then allowed those programs to move forward. Senator Johnson. I pointed out in a meeting like that, a panel, for Duchenne Muscular Dystrophy, 50 to 60 families, and they still said no. Ms. Kennedy. I love that reference. What you may not know, you probably don't know, is prior to being with the EveryLife Foundation, I was with the Duchenne community, and so that may have been an advisory committee. Senator Johnson. Were you in that meeting? Ms. Kennedy. Yes, I was. Well, it depends on what meeting you are referring to. If it was an ADCOM, an advisory committee meeting, that advisory committee did vote no, but then the agency brought that internally and then overruled that. Senator Johnson [continuing]. overruled it. Ms. Kennedy. That is a perfect example of the agency still has the authority to make the decision because they heard from the community and what we are concerned about right now is that the agency isn't engaging with the patient community. Senator Johnson. Dr. O'Neill, in your testimony you talked about, you got your CO, the complete response letter. I mean, perfect bureaucratic type of--in other words, the no letter, right, and you got the no letter, not necessarily because of safety or lack of efficacy. It was because there is something in the manufacturing process, which again, a manufacturer, I understand that, but can you explain that. It seems like a pretty weak excuse where you could, we will fix the manufacturing process so this drug can be made available just talk about that Dr. O'Neill. Thank you. I am not an expert on gene therapy manufacturing, so I will say that. However, the sponsor was very transparent in reviewing the full CRL with our community so that we could understand truly what the concerns were. Many of them were noted to be things like a crack on the floor not in the manufacturing area, or a tarp that was out back, or things that really are unrelated to our children. Senator Johnson. Trust me, I have been through audits. I supplied packaging material for medical devices. You can find an excuse to, you know, write something up, pretty flimsy excuses. Again, that is my concern. Dr. Schmahmann, in your case, it was based on real world evidence. It seems like the real-world evidence was completely in favor of allowing patients access to this drug. Talk a little bit about, you know, why you got a CLR, a no letter. Dr. Schmahmann. Thank you, Senator. You know, one of the thoughts that came to me as we are going through this whole process and hearing what happened to Sanfilippo with the crack in the floor in the factory is that this is a policy of death by technicality. These little, tiny glitches that the FDA is producing land up not approving drugs and patients die as a consequence. I am glad to hear that there are people in the FDA who are doing what Congress requires them to do, but that speaks to the unpredictability and the erratic nature of the responses and the performance of the people in FDA. There are many ways to go forwards to use clinical trials and then use the new technology to bring treatments to patients faster that are safe and make a difference. Science advances. The regulation is keeping up with the new advances, but it seems like the FDA is having trouble with that. The FDA must keep pace with the updates in science using the biomarkers, serum or imaging, using digital markers, using patient reported outcomes. I developed the patient reported outcome measure for ataxia, understanding what patients are saying. The key issue here is that the real experts are the patients. The patients are the experts by experience. The patients are our research collaborators. We are all patients. Every one of us has something. We are all patients. It may not be a rare disease, but this applies to us. We are talking about us, whether it is a rare disease or not. The approach that can be taken, including what was started at our institution, I think called a platform trial, where you can have one small group of controls and a number of other patient cohorts trying different drugs. There are innovations both in the clinical trial design and the biomarker space. This is where we need to move, and the urgency is exactly what Senator Kim was talking about. There is an urgency now and some of the drugs on the table now, the ones you have heard about from Dr. O'Neill and myself, these should be approved this week. There is no reason not to. Going forward, we need to find a way to enhance, to expedite, and make this a better process and have a sense that when you are going to the FDA, you know what you are getting. It is not just a random scatterplot of who is going to get what kind of a person there. Senator Johnson. Isn't another root cause here is literally the doctors are no longer at the top of the treatment pyramid? They have been replaced by regulators. You talk patients are number one, but doctors are the ones that are most knowledgeable in this equation, and you are shutting off to the side. What you are saying doesn't count because the regulators have replaced you in terms of making these decisions for patients. Isn't that a big problem? Dr. Schmahmann. You know, Senator, on your wall in your office yesterday, I saw your mission statement, which was triple, teamwork, respect, integrity, professionalism, loyalty, and education. The FDA is not doing that. It is the opposite. Communication, dialog, teamwork between the physicians, the patients, the pharma who make the drug, the regulators, that is a two-way street. It is a dialog. In medicine, when we do rounds in the morning on our patients in the hospital, there is a discussion. The physician is there, the residents are there, the nurse, the nurse practitioner, or the physical therapist, the patient and the family. It is a conversation, a discussion. This is not what we are hearing from across the board and certainly from the other rare diseases. We are here, the few of us. Turns out there are 30 million people behind us, as you said. What we are bringing to you is the plea to make the FDA what it was supposed to be, which is what you regulated, and allow us to work in a collaborative manner across the board, not with this kind of hit or miss approach as to who you are going to get on a committee. You are looking for accountability. In fact the leadership of the FDA, it is their responsibility to hold the feet to the fire of the people under that person's leadership. Not just to say good things, but to actually make them happen and bring new drugs to the American population including us, our patients, my patients, that are safe and effective. Senator Johnson. Again, thank you, Mr. Chairman. I think this is an excellent hearing, excellent testimony. Both you and the ranking member, you pretty well diagnosed the problem here. I mean, in your opening statements, you laid out the problems. This is eminently fixable, and we have to fix it. Again, I am committed to working with you to do so but thank you for this hearing. The Chairman. Senator Gillibrand. Senator Gillibrand. Thank you. In 1972, the Federal Advisory Committee Act established advisory committees within the FDA to help provide independent expert scientific input on product reviews and policy topics. In 2025, FDA canceled many advisory committee meetings and indicated that it would like to move away from involving advisory committees in the review of drug applications. For each of the witnesses, you can start Ms. Kennedy, how important is it to the rare disease community for FDA to restore the use of advisory committees? Ms. Kennedy. It is everything. We yesterday had one of our communities showcase in front of close to 800 members of the rare disease community how an advisory committee meeting helped inform a key regulatory decision for the VAR syndrome community by showing how an open public hearing enabled members of that community illuminate the nuance of a very complex regulatory decision in a very complicated regulatory review. As Senator Johnson just highlighted, I have been a part of many advisory committee meetings for communities, including the Duchenne community, and advisory committees don't always vote yes. That is not the point. The point is for external experts, including clinicians, including those with statistical expertise and manufacturing expertise that are not always internal to the agency, to be brought to bear on regulatory decisions because we realize that with 10,000 rare diseases, it is not possible for FDA to always have all of that expertise internal. Those committee hearings must be at the avail of the agency, but also those open public hearings must be available so that patient communities who are participating in clinical trials can share what their experiences in those clinical trials are. One of the challenges we have in clinical trial design is we don't always know what we are going to find when a clinical trial begins. We design a clinical trial hoping that we are going to be able to select the best outcome measures, but sometimes patient communities who participate in those trials experience other benefits and those hearings enable us to hear from patients about what other outcomes were achieved so that we can make the best decisions possible for the patient community around safety and efficacy. Eliminating those hearings eliminates the chance for FDA to make the decisions that are in the best interests of the patient communities possible. Senator Gillibrand. Dr. Schmahmann and Dr. O'Neill, congressional actions have advanced how patient experience data is included in the development and evaluation of rare disease therapies. What is the importance of the patient voice in this regulatory process, and what more is needed to ensure FDA includes this information in its decisionmaking? Dr. Schmahmann. I agree that it is critical, Senator. I think that there is a deeper problem. If you don't listen to somebody else's advice in a complex story, that is the opposite of humility. It is a denial of the patient's humanity and it is sort of hubris. You don't want to hear what the patients have to say? Who are you? That is the problem. This is all about the patients. To deny the patient voice in drug development and in drug design--and I agree completely with Ms. Kennedy here. Determining the end point when you start is fine if the disease is well known in the millions of people. In our case, for example, the spinocerebellar ataxia, the first clinical trials that Biohaven did in the 2016s, we didn't know what would change. We had to take a guess and I worked with them in devising the scale, devising a trial. The patients then told us, you know what, I am falling less, I am not as fatigued, and my speech is better. There was a different outcome we didn't understand at the beginning. That is the epitome of regulatory flexibility. There is a rule in medicine, listen to the patient, they are telling you the answer. The second piece is, ignore the patients at your peril. What we have here is denying of the patient's story. It is the peril not of us, but of the patient because now the drugs are not being approved. I think you have hit the nail on the head here. If you are ignoring the patient, then why are you getting up in the morning and coming to do the work that you do with the FDA? Senator Gillibrand. Well said. Dr. O'Neill. Dr. O'Neill. Thank you. You know, obviously you have heard that patients are not outside of the drug development process. They are critical to it and advisory committees, as Annie had mentioned, are an important place where we can have that scientific dialog and hear from patients. Their experience is also science. It is human science. The interaction needs to come way before that, because by the time we get to an advisory board, tens of millions of dollars have been spent, maybe a decade has gone by. We have not treated potentially that many patients who needed treatment. Having a true collaborative dialog early in the process is essential and something--an opportunity that needs to be acted upon within the FDA. I think one other thing that we are understanding is key insights around risk tolerance. We also want safe medicines, but we also want the opportunity to save our children because those answers about a clinical trial come way down the road. As Mr. Campbell explained, real-world evidence, post- marketing disease monitoring programs, this is where we need to be really focusing on these innovative ways. Maybe not so innovative, honestly, anymore, but more frequently used and supported ways to provide that longer term evidence to support accelerated approval. Senator Gillibrand. Mr. Campbell, did you want to add? Mr. Campbell. For sure. I think what we keep coming back to, and I think you hear the theme, is you have all the tools in place. You have the advisory committees. You have accelerated approval pathways. I think the frustration is when they are deployed inconsistently and without clarity from the sponsors and from the patient community and from the physicians in terms of how you end up, you know, meeting the expectation but then not coming to a positive resolution. There is one other piece that we haven't talked about, if I could just introduce that, which is the Rare Disease Innovation Hub. If we want to talk about things that Congress could proactively do. We have a tool that is modeled after what was very successful in oncology, the Center of Excellence, but my observation would be is it is underfunded and probably under empowered to do what it needs to do. When we think about advisory committees, when talk about staffing at the FDA, when we think consistency between reviewers, Congress could directly fund the Rare Disease Innovation Hub in a meaningful way that would allow us to train rare disease experts that could sit across review teams, across review divisions, and bring some of that consistency, that humanity, that humility, but that expertise that perhaps each of the individual teams or the new reviewer on the team doesn't quite have. Again, I think we have a lot of the tools that we need. We just need to encourage the FDA to use them in the right way and that is one example we haven't talked about here today where Congress could fund that directly and allow the FDA to make it a much more valuable tool for rare disease drug development. Senator Gillibrand. Thank you, Mr. Chairman. The Chairman. You know, when you hear the testimony, I think all of us internalize it. I have got six grandsons and a granddaughter and you know, thank God they don't--you know, everybody has got problems, right, but you know, they don't have a rare disease that is going to shorten their life. I can't imagine what a family is going through when they have a family member that has something and then they believe there is a possibility that something could change their life, and it doesn't happen. I mean, I would be pretty frustrated. I would be pretty--more than that. Ms. Kennedy, is it important for people to come to Congress and talk about their concerns with regard to the drug approval process? Ms. Kennedy. Well, I know you are asking me, but there are about 800 people on the Hill that would be happy to answer that question as well. Throughout this time here this morning, starting with your opening remarks, we have cited many laws that have been transformational for our rare disease community, and every single one of them started with a member of the community meeting with their elected official and talking about a roadblock that could be transformed and turn into a resource and a tool. Every single one of those laws has transformed lives and ultimately has saved lives. So the answer to your question is an emphatic yes, and we are so grateful for the time you take to be with our community, to listen to our community, to engage, and to become partners with all of us, so thank you. The Chairman. Does the FDA appreciate when you guys come here? Ms. Kennedy. I think many do, yes. Maybe some no, but I think overall, over the years, I have been in this space 30 years and I think we have had strong partnerships with the agency and many times the agency has very much appreciated our support. The Chairman. Dr. Schmahmann, what--from a clinical standpoint, what happens to patients with progressive neurologic diseases when access to treatment is delayed due to the regulatory process rather than safety concerns? Dr. Schmahmann. They progressively deteriorate. They lose function. They can't live their lives, go to work, spend time with their family, make a living, be productive citizens of society in that way. They become part of the family that people have to take care of instead of taking care of the families themselves. Then they become progressively debilitated and then they die young. Then family members, in our case, see that. They see their future in the mirror. There is a high incidence of depression and, in fact, suicidality in this patient community as well. This is across the spectrum. This is not a motor control problem alone. This is a social, emotional, societal issue and the issue about medications that improve neurological function in real time work at the level of the physiology where brain cells are sick before they die. If you have a medication, even though it is not a gene therapy, you have medication like troriluzole, where we know the mechanism, and you stop the neurons from being so hyperactive that they die, you actually improve function and you slow disease over time, so you are modifying the disease. The absence of a medication that can treat the disease means that each day that this drug, troriluzole, and others like it are not being approved means patients are losing brain cells and are closer to death. It is heartbreaking to see, as you all said at the outset, and we are hoping that this can change from today. The Chairman. I think in your testimony you said that the FDA suggested withdrawing patients from compassionate use of care to evaluate whether their conditions would deteriorate despite physicians expressing the harm would be irreversible. So tell me about the--what are the ethical implications of that? Dr. Schmahmann. If you have a disease where there is a symptom like a migraine, for example, you can see if I stop the drug, will you get worse for a week or two, or a month, and I will put you back on drug, you are okay. In a neurodegenerative disease like these, and I am going to be--excuse me if I am provocative--the last time we had a catastrophe in medical science in the U.S. was between 1922 and 1972. I believe there was like a 40-year period, 1932 to 1972, when people with syphilis were not treated so that the doctors could see what happened to them, and the patients were not told. That is a case study for every person who is going into human studies research in the United States. We learn about that case. You cannot treat patients like guinea pigs. You have to have them on your story as part of the research collaborator, experts by experience. If we have a drug, as we do here, that is first safe and that bends the arc of the disease, and you want patients to come off that drug so you can see if they worsen, in other words if their brain cells are dying under your care, that is a poster child--it is Tuskegee version two, and it is entirely unacceptable. I reject it outright. They should not have recommended that and whoever did, I would suggest they take updated education sessions on clinical trials and on human studies research. It is not okay, Senator. The Chairman. I can't imagine doing that. Mr. Campbell, talk about inconsistent FDA standards, how it impacts timelines, costs, the ability of small biotech companies to survive. Is it easier to raise money if the FDA is inconsistent? Does that make your job easier? Mr. Campbell. No, is the candid answer, and you know, that is underlying all of this, right. We have created in the United States this rich ecosystem of innovation, which has been supported by Congress, supported by FDA over the years, supported by modern technology, and that brings in new companies that bring in new innovations and offer some of the therapies that we have talked about here today that are now stuck in front of this regulatory process. The reality is, and this is in my written testimony, the reality is for many small and mid-sized biotech companies, it takes decades to become profitable, which means we are going hand-in-mouth begging for dollars from investors. If there is a clear path forward and investors can be confident of an eventual return, then they will keep investing and the innovation ecosystem keeps going and going. If we continue to create this uncertainty, if we continue to create an uncertainty around manufacturing timelines, around approval timelines, around changing the goalposts again, I am confident that those investor dollars will go somewhere else. I will tell you transparently, having gone to the recent J.P. Morgan Healthcare Conference, which I am sure folks know is the big investor conference in our industry, I heard more opportunities about Chinese therapeutics and companies than ever before, and I don't think that is an accident. Ten, twenty years ago, we might have thought the science wasn't good. We might have distrusted the quality and the safety. I can tell you that the innovation there and the science is equally as good as ours. We still have an advantage, but if we are not careful, we are going to lose that advantage, and at the end of the day, the American patients suffer, the American economy suffers, and I am convinced that that is a real threat, in addition to the most important piece, which is making sure drugs get to patients faster. The Chairman. Dr. O'Neill, in progressive rare diseases, how should regulators account for the fact that clinical decline is often irreversible? Should the harm of waiting be weighed alongside uncertainty in the data? If so, how? Dr. O'Neill. Thank you. Yes, to call back to Dr. Schmahmann's points around this and about exposure to not being on drug, the risks of not treating this disease are known. You know, these are not in question. We know these children will be permanently, severely brain injured for the rest of their lives. There are critical, time- sensitive neurodevelopmental windows in childhood when it is important to intervene to be able to receive the maximum benefit. There is a continuum of this, but earlier is always better. What we are still hearing as recommended to sponsors is that observational, or no treatment, or placebo controlled trials are being recommended for these pediatric conditions. This is very, very troubling when we know that they will become brain injured. We have also seen--you know, when parents ask me about this, I have to kind of step back and think, oh my goodness, I know what a perfect science experiment looks like. Yes, that is the perfect science experience, but these are children. You cannot do good medicine unless you are putting the patients first and following the ethics of medicine and we have heard changes around the use of animals in preclinical studies. Just last April, the FDA published its roadmap to reducing animal testing in pre-clinic studies, and this says, I quote, "due to the limitations of animal testing as well as ethical concerns about animal testing, there have been increased focus within the scientific community on new approach methodologies." We are concerned about the ethics of animal testing more than we are concerned about the ethics of allowing children to be brain injured in clinical trials, and I think we all need a gut check on that. The Chairman. Would any of you like to talk about what patients and caregivers tell you about their willingness to accept uncertainty or incomplete data when the alternative is no treatment at all? Dr. Schmahmann. I think it starts off with safety. Nobody likes side effects, and patients do want to know that the medications are safe, or the approaches are safe. Given that piece, if we can make a comment about safety, the degree to which the medication works or not is often something that patients, I think, are willing to take on. We can certainly hear from the others about that and the other rare diseases. In our space, knowing that the medications we have available are safe, and have been shown in other circumstances, patients are not just willing, they are--we are getting emails every day from people around the world, what trials do you have for me that I can use to try and slow down the process of my disease? Ms. Kennedy. Yes. I really appreciate that question, and I think my response would be that for each subpopulation within each condition, within each targeted therapy, that consideration would be very different, which is why Congress authorized the use of the benefit-risk framework within the consideration of regulatory review. That is one of the things that we are concerned about is not being applied. We don't know how it is being used. One of the things that we are asking for today is more questioning around how are these tools being utilized, because every community for every clinical trial within every subpopulation of that community will approach that threshold for risk tolerance differently. That is a super important question, Senator, and we are just not sure that that is being questioned the way it was intended for the tailorization that is required for rare disease therapeutic development. The Chairman. Mr. Campbell, can I ask you a separate question? How important is transparency from the FDA in maintaining trust with rare disease communities? What happens when explanations for delay are unclear or incomplete? Mr. Campbell. You know, I feel like as sponsors, manufacturers, we have a great duty to our patients. I think somebody--one of the Senators asked me why I am in this business. I will tell you, you know, it is for the patients, but when you have a chance to develop a therapy for people living with a rare disease, it sort of gets in your blood. You also, then you bear a great responsibility. I feel, I think, like sponsors are at the front lines, in front of the agency trying our best to get those drugs over the finish line. If we fail to do that for any reason, we owe it to the patients, to the community, to the caregivers to give them an explanation. When there is no good explanation or when the explanation is a crack on the floor, you know, that is just not good enough. I think I really do believe that sponsors bear some of that responsibility. I think it works best when we truly work together. Congress has the tools. The FDA has proven itself over time to be very effective in working with sponsors. I shared our story, which was an incredible, innovative regulatory science, medical science that helped thousands of patients. If you don't have that transparency, and if you do not have that consistency then, you know, we all lose, and I really believe that we are at the center of that. It pains me, you know, to hear these stories. We are not in that position today as Amicus, but we owe a responsibility to these people who are giving their lives to participate in clinical studies who have so much hope, we owe them clarity and we all do. Everybody who is involved in that, including the regulators. The Chairman. Ranking Member Gillibrand, you want to say anything before we close? Senator Gillibrand. I would like the audience members who have pictures of their loved ones to stand please so we can see their loved one. Thank you for coming to represent them. Thank you all. I want to just thank our guest who is in the corner who has been so well behaved this entire time. I am very proud of her for being such a good girl. Just thank you all for being here today. This has been an extremely powerful hearing. We have gotten some amazing testimony, and I am very hopeful that we will find better solutions so that we can all work together to get these cures that our loved ones so desperately need. Thank you all. The Chairman. I want to thank everybody for being here. I want to thank the Ranking Member for this. We have been doing this for a little over a year, and we have been able to do a lot of things together. What we heard today was not abstract policy theory. We heard from Mr. Campbell that 95 percent of rare diseases still have no approved treatment. At the current pace, it could take more than a century to meaningful close that gap. We heard Dr. Schmahmann about a multi-year data set supported by real-world evidence and natural history comparisons, showing meaningful showing of disease progression, yet still unable to clear the regulatory bar. We heard from Ms. Kennedy that at least 23 rare disease therapies received complete response letters in the past year, even as advisory committee meetings declined, raising concern about whether the flexibility Congress authorized is being applied consistently. We are reminded that for some patients, success is not an abstract endpoint, but the ability holds one breath long enough to survive another moment. I recently spoke with Commissioner Makary. It was clear that the FDA's framework was built for common diseases, not rare to ones. He is implementing reforms like the plausible mechanism pathway, greater flexibility for gene therapies, and strengthening the rare disease innovation hub. We look forward to working with him to ensure those changes are applied consistently and urgently for patients. He inherited a broken system, and the FDA cannot be fixed overnight. That said, he has made significant progress, and I am completely encouraged by the reforms President Trump has empowered Commissioner Makary to make at the FDA, and I know he cares deeply about getting results and making sure the United States remains the world's leader for innovation and treatment of rare diseases. Taking together the testimony presented before our Committee today makes one thing clear, the question is not whether to protect safety, it is whether the system is moving with the urgency Congress intended and patients require. The Committee will continue exercising oversight to ensure that flexibility enacted into law becomes reality in practice. I look forward to continuing work with our members. If any Senator has additional questions for the witnesses or statements to be added, the hearing record will be open until next Wednesday at 5:00 p.m. Thanks everybody for being here. [Whereupon, at 11:05 a.m., the hearing was adjourned.] ======================================================================= APPENDIX ======================================================================= Prepared Witness Statements ======================================================================= [GRAPHIC NOT AVAILABLE IN TIFF FORMAT] ======================================================================= Questions for the Record ======================================================================= U.S. Senate Special Committee on Aging "From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation" February 26, 2026 Questions for the Record Annie Kennedy Senator Raphael Warnock Question: Over the past few decades, the FDA has adopted strategies to accelerate the development of treatments for ultra-rare diseases. These strategies have included the Support for Clinical Trials Advancing Rare Disease Therapeutics Pilot Program, Rare Disease Evidence Principles, and the Plausible Mechanism of Action Framework. However, there are many rare diseases that still need treatments. What would be the advantages of the FDA extending the above strategies to other rare diseases? How can Congress ensure the FDA balances acceleration and thoroughness in its review of potential rare disease treatments? Response: We have been following closely the recent agency announcements, including the Rare Disease Evidence Principals (RDEP) initiative, the Plausible Mechanism Framework, the establishment of the Rare Disease Innovation Hub in 2024, and the implementation of new guidance documents and regulatory science pilot initiatives contained in PDUFA VII (10/1/2022 - 9/30/2027). The application of these programs and policies can shape the prospects of rare disease therapy development for a given community, drive investment into one area and out of another, and determine how patient advocacy organizations allocate precious resources. For a variety of reasons the ways in which available guidances, programs, and pathways can be applied to different subpopulations of rare diseases differ. Multiple factors have led to some rare disease communities having greater success in leveraging FDA's regulatory flexibility including population size, therapeutic modality, disease characterization, extent of diagnostic delays, age of onset, and others. We are encouraged by the intent signaled by FDA's most recent initiatives, RDEP and the Plausible Mechanism Framework, however, more information is needed to understand how the Agency plans to operationalize these new approaches for products in today's pipeline and beyond, and which subpopulations of rare diseases stand to benefit initially, and over the longer term. We encourage additional dialogue and input from the community into these new initiatives as even the best ideas need the benefit of robust dialogue and operational details for them to have the intended effect. Specific to the RDEP announcement - this announcement appears to be responsive to calls for more predictability in the regulatory process, but more details will be needed before we have a detailed reaction. Many rare disease communities may not realize the program's benefits due to its narrow focus; however, it can provide valuable insights for expansion if appropriate metrics and evaluation methods are incorporated from the outset. We are eager to hear more details on how RDEP will be operationalized, as well as a better understanding of how RDEP's requirements for pre-specifying the trial requirements will be handled, given the nature of many rare disease trial designs. Regarding the Plausible Mechanism Framework, we are encouraged by the release of the draft Guidance, and what it represents for the eligible communities for whom traditional approaches to clinical trials and regulatory requirements are fundamentally at odds with the reality of their conditions. We are grateful to the FDA for taking on this challenge of ensuring no disease is too rare to deserve treatment. And we are incredible grateful to the many families and experts who applied their personal expertise to yield transformational change. We also recognize that for many in our rare disease community, the Plausible Mechanism Framework will not apply, and we urge FDA leadership to continue pursuing solutions that will ensure the tools and policies that Congress has created over decades, are deployed in a predictable and consistent manner that can unleash scientific innovation and speed safe and effective therapies to patients across the more than 10,000 rare diseases. The EveryLife Foundation team is in the process of closely reviewing the recently released draft Guidance. Regarding the Rare Disease Innovation Hub and opportunities yielding from PDUFA VII Pilot Programs, we are hopeful that the opportunities stemming from these PDUFA VII investments will be applied more broadly across rare disease product development. The Rare Disease Innovation Hub is well positioned to be a catalyst of progress by spearheading the dissemination of data, case studies, and other learnings resulting from these pilots and experiences with the application of regulatory flexibility tools more broadly. Since 1983, Congress has created incentives and policies that recognize the inherent complexities in developing treatments for rare diseases. Congress has explicitly given the FDA authority to uphold the highest standards of regulatory safety and rigor, while applying tailored approaches (i.e. "regulatory flexibility"). Such approaches include: Establishment of the accelerated approval pathway Consideration of the totality of evidence in the regulatory review Inclusion of Patient Experience Data (PED) in clinical trial design & regulatory processes Utilization of innovative clinical trial designs and real-world evidence (RWE) Nearly 1,400 orphan-designated therapies are changing the lives of patients and families, but 95% of rare diseases remain without an FDA-approved treatment. Congress must continually ensure that FDA review statutes keep pace with the science and are designed to work across the spectrum of rare diseases, from n-1 to just under 200,000, and from pediatric to adult populations. Congress should look to address gaps more regularly, ideally more often than the typical practice of moving regulatory legislation alongside the five-year PDUFA reauthorization window allows. Congress should regularly engage in dialogue with the Agency leadership and rare disease stakeholders, seek comprehensive metrics to understand how the Agency is applying regulatory flexibility, and ensure the Agency has adequate resources, such as funding for the Rare Disease Innovation Hub, to optimize their ability to apply tailored approaches to rare disease product evaluation. Question: As part of his sweeping reductions-in-force (RIFs) of Department of Health and Human Services (HHS) employees, HHS Secretary Robert F. Kennedy dismissed 3,500 Federal Drug Administration (FDA) employees in April 2025. The RIFs targeted employees across the agency, including advisory committee staff. You mentioned that the FDA held far fewer advisory committee meetings in 2025 relative to 2024 and that this drastic drop meant fewer opportunities for experts and patients to share information to inform the FDA's decision-making. What are the ramifications of last year's RIFs at the FDA for the development and treatment of illnesses that do not yet have a cure? Response: Significant leaders the rare disease community has built relationships with over the years have either resigned or been laid off in the last 12 months, resulting in the loss of powerful allies and institutional knowledge that have generated the progress the rare disease community has seen over the last decade. However, thousands of committed public servants remain, and the EveryLife Foundation, together with our community, is committed to policies that will support and enhance the Agency's rare disease capacity and expertise. Rare disease product reviews occur in every division and product Center at the FDA. With the appropriate resources, the Rare Disease Innovation Hub is poised to enhance its role as the FDA's coordinating office to optimize rare disease expertise, processes, and engagement with stakeholders across all therapeutic areas, including drugs, cell and gene therapies, and medical devices. Given the departure of experienced staff, the importance of a robust Rare Disease Innovation Hub is magnified. The Hub's first full year of operations has laid the foundation for meeting this moment of opportunity if institutional support and resources are enhanced. Question: How can Congress conduct oversight over the FDA to ensure the agency continues to hold advisory committee meetings and review rare disease treatments? Response: We are concerned about the dramatic decline in opportunities to leverage external scientific, clinical, and patient-community insights to inform deliberations on complex rare-disease product reviews. While not every product application requires an advisory committee, where relevant, their use was one of the few ways the Agency discussed its approach to the review in public and heard from clinicians who treat patients and run trials, and from the patients and families who took part. This additional insight affords review teams with another data point to consider among the totality of evidence they must balance when determining how to apply the regulatory flexibility tools that Congress has authorized. As I encouraged Congress in my testimony, Congress should conduct outreach to the Agency to understand its approach to the following: The application of the accelerated approval pathway to rare disease therapies; Improving the predictability and consistency of the application of regulatory flexibility; and Resuming the use of Advisory Committee Meetings to receive external expertise on product reviews and key policy topics. Based on this engagement and the Agency's responses, we encourage Congress to identify opportunities for additional public dialogue with the Agency and rare disease stakeholders to identify a path forward that will ensure sustainable, transparent, and predictable processes for leveraging external expertise in relevant product reviews and to inform overall rare disease regulatory science approaches moving forward. U.S. Senate Special Committee on Aging "From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation" February 26, 2026 Questions for the Record Bradley Campbell Senator Raphael Warnock Question: Approximately one in ten Georgians live with a rare disease. Many of these individuals, including older adults, do not have access to life-saving treatments due to incomplete scientific knowledge of their disease and limited funding. Families seeking treatments that were reviewed under a priority voucher program are also experiencing delays due to the prolonged FDA approval process. How can Congress reduce regulatory barriers to expedite the FDA's approval process for rare disease treatments while maintaining the safety and quality of these treatments? Response: Senator Warnock, thank you for this thoughtful question. As noted in my testimony, I believe there are low-hanging fruit that we can seize while still maintaining FDA's "gold standard" for safety and efficacy: Speeding up approval of early phase clinical trials Harnessing innovative endpoints based on biomarkers Expanding the use of real-world evidence Streamlining manufacturing inspections In cases where there is residual uncertainty about the durability or extent of patient benefit for promising therapies, real-world data should be collected post-approval via the Accelerated Approval pathway.\1\ If that data does not bear out patient benefit, the agency should consider withdrawing that treatment in consultation with the patient community. When it comes to rare diseases, patients and their families are the true experts, and their voices need to be respected as such. --------------------------------------------------------------------------- \1\ Examples of rare-disease therapies that entered the market via FDA Accelerated Approval and later converted to full approval include sparsentan for primary IgA nephropathy, agalsidase beta for Fabry disease, and delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy. --------------------------------------------------------------------------- FDA already has Congressionally granted authority to do everything I listed above. The challenge is simply doing them consistently. This is where Congressional oversight is vital. Question: How do bipartisan initiatives like the FDA Pediatric Priority Review Voucher program, which I was glad to see reauthorized recently, help incentivize innovation for rare disease treatments? Response: Senator Warnock, we are deeply grateful to Congress for reauthorizing the FDA's Pediatric Priority Review Voucher (PRV) program. Small and mid-size biotech companies are the driving force behind U.S. drug development for all diseases, but particularly for rare diseases. These companies are often pre-commercial, meaning they are years-to-decades from sustainable profitability. When a company with a PRV voucher receives FDA approval, the sponsor can sell that voucher, sometimes for hundreds of millions of dollars. That funding is a critical lifeline for continued operations when the alternative is bankruptcy. Rare pediatric diseases that have benefited from PRVs include pediatric neuroblastoma, the most common cancer in infants; spinal muscular atrophy (SMA), the most common genetic cause of infant mortality; and epidermolysis bullosa, which causes fragile, blistering skin. There we no treatments for any of these diseases before Congress created the PRV program in 2012. The PRV program has no cost to taxpayers, but when investors are considering whether to fund an early-stage rare disease company, having a PRV designation can be decisive. ======================================================================= Statements for the Record ======================================================================= [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] [all]